Four batches of injection drug recalled

Due to potential quality issue.

According to a report, the Department of Health is monitoring the voluntary recall of four batches of Ambisome for Injection 50mg from the market due to a potential quality issue.

Its licensed drug wholesaler, LF Asia (Hong Kong) - Healthcare Division, notified the department that the product's manufacturer in Ireland detected contamination at the manufacturing facility during its routine process sterility testing.

According to the company, the affected batches of the drug have been imported to Hong Kong since January, with about 3,000 affected bottles supplied to the Hospital Authority and private hospitals, local pharmacies and private doctors.

It has informed all affected customers about the recall. So far, none of the Ambisome injections have been found to be contaminated and the department has not received any adverse reaction report related to the use of the product.

Call the company’s hotline 3129 2037 for enquiries.